Ask any environmental monitoring team which cyanotoxins they screen for, and you’ll hear the same list: microcystin, anatoxin-a, saxitoxin, cylindrospermopsin. What you almost never hear is guanitoxin — and that silence is a serious problem. Guanitoxin is an organophosphate neurotoxin produced by freshwater cyanobacteria, ranked among the most acutely lethal cyanotoxins known, and it is almost entirely absent from routine HAB monitoring programs worldwide. As harmful algal bloom funding and research enters a new phase in 2026, understanding this detection gap — and how to close it — is essential for any team working in water quality, environmental surveillance, or HAB risk management.

Guanitoxin (formerly known as anatoxin-a(s)) is a potent anticholinesterase produced by freshwater cyanobacteria including Sphaerospermopsis torques-reginae and certain Anabaena and Dolichospermum species. It works by irreversibly inhibiting acetylcholinesterase — the same mechanism as organophosphate nerve agents — causing neuromuscular paralysis and death in mammals at extremely low doses. It has been linked to livestock and wildlife fatalities across multiple continents.

Despite this toxicity profile, guanitoxin is not currently included in routine environmental monitoring programs — not by the EPA, not by most state agencies, and not by the majority of international water quality frameworks. The reason is largely technical: guanitoxin is chemically unstable in the environment, degrading rapidly under oxidative and alkaline conditions. This instability makes it incompatible with many standard analytical workflows that work well for more stable toxins like microcystin. The result is a toxin that can be present and dangerous in a waterbody, yet completely invisible to the monitoring teams tasked with protecting public health.

A landmark 2022 study published in the Journal of the American Chemical Society changed the scientific picture significantly. Researchers at Scripps Institution of Oceanography decoded guanitoxin’s complete nine-step biosynthesis pathway from l-arginine, identifying the gene cluster responsible for its production. Critically, when they screened environmental sequencing datasets from municipal freshwater bodies with histories of toxic bloom events, guanitoxin biosynthesis genes were repeatedly detected and actively expressed — in waters where no one had been looking for the toxin at all.

On May 7, 2026, the New York State Department of Environmental Conservation announced the launch of its HAB Research Grant Program, calling for innovative, novel, and well-integrated research studies targeting prioritized HAB research topics as part of a statewide strategy to reduce harmful algal blooms and their impacts on public health and the environment. This kind of dedicated public funding signals an important shift: agencies are no longer treating HABs as a seasonal nuisance to be managed reactively. They are treating them as an enduring and escalating public health infrastructure problem — one that demands better science, better tools, and a broader toxin scope than current programs cover.

The timing matters for any laboratory or monitoring program evaluating their current cyanotoxin panel. If your workflow stops at microcystin and cylindrospermopsin, you may be delivering a false sense of safety — particularly in freshwater systems where bloom-forming cyanobacteria capable of producing neurologically active toxins are documented. A January 2026 review published in Toxics confirmed that rising temperatures and anthropogenic nutrient loading are increasing the frequency and geographic range of toxic cyanobacterial blooms globally, with neurotoxin-producing species expanding into previously unaffected watersheds.

Until validated rapid immunoassay formats for guanitoxin become broadly commercially available, monitoring programs face a practical question: how do you manage the risk of a toxin you cannot easily screen for at scale? The answer lies in two complementary strategies — broadening your neurotoxin surveillance panel using available rapid tests for related cyanotoxins, and building molecular early-warning capacity using gene-targeted detection.

On the rapid testing side, the neurotoxins most closely related to guanitoxin in terms of mechanism and ecological co-occurrence are anatoxin-a and saxitoxin. Both are produced by overlapping cyanobacterial genera, and waterbodies capable of producing guanitoxin are often capable of producing these toxins as well. Screening for the full neurotoxin suite — rather than limiting surveillance to hepatotoxins — gives monitoring teams a far more complete risk picture, even while guanitoxin-specific immunoassays continue to develop.

Attogene’s Anatoxin-a (ATX) Detection Kit for Recreational Water (SKU: AU2062) uses a patent-pending recombinant acetylcholine receptor (AChR) surrogate bound to colloidal gold — a genuinely novel mechanism that responds to anatoxin-a in a concentration-dependent, isomer-specific manner. The kit detects ATX at or above 7 ppb in recreational water and algae culture matrices and has been validated against multiple cyanobacterial strains including Oscillatoria brevis, Anabaena flos-aquae, and Anabaena subcylindrica. For lab-based workflows, the Anatoxin-a Rapid Lab Kit (SKU: AU2062-1) provides the same AChR-based chemistry in a format optimized for controlled laboratory environments.

For freshwater stream and source water surveillance, Attogene’s Saxitoxin (PSP) Lateral Flow Kit for Freshwater (SKU: AU2057) screens saxitoxin at concentrations as low as 70 ppt with a 15-minute run time — fast enough for active field deployment during bloom events. Shellfish monitoring programs can use the companion Saxitoxin Shellfish Rapid Test (SKU: AU2057-01), which screens tissue extracts at or above 50 ppb, consistent with established action level guidance for paralytic shellfish toxins.

A complete multi-toxin monitoring strategy pairs neurotoxin surveillance with robust hepatotoxin screening. Microcystin remains the most frequently reported cyanotoxin globally and the primary analyte in EPA Method 546 compliance workflows. Attogene’s Microcystin Rapid Detection Kit for Recreational Water (SKU: AU2024) provides field-deployable qualitative screening, while the Microcystin Rapid Kit for Drinking Water (SKU: AU2024-02) achieves sensitivity down to 0.1 ppb — appropriate for finished water compliance monitoring. For quantitative laboratory confirmation and Method 546 workflows, the Congener-Independent Microcystin/Nodularins ELISA Kit (SKU: EL2024-05) provides comprehensive coverage across more than 50 microcystin congeners.

For programs tracking cylindrospermopsin — the hepato- and nephrotoxin that has expanded dramatically into temperate watersheds over the past decade — Attogene offers both the Cylindrospermopsin ELISA Kit (SKU: EL2047-02) for quantitative lab analysis and a field-deployable rapid detection format. Together, these tools allow environmental labs and monitoring agencies to implement a tiered, multi-toxin HAB surveillance program that covers the full range of toxin classes that current evidence identifies as public health risks.

The guanitoxin detection gap is a useful lens for a broader principle in HAB monitoring: toxin panels built around regulatory minimums will always lag behind the biological reality of what cyanobacteria produce. Monitoring programs that want to get ahead of that curve — and that want to be competitive for the new wave of HAB research grant funding — need to demonstrate they are screening for the full toxicological landscape, not just the analytes that existing standard methods happen to accommodate.

A practical multi-toxin approach combines field-deployable lateral flow assays for rapid triage — screening for microcystin, anatoxin-a, and saxitoxin at the waterbody — with confirmatory ELISA quantification back in the laboratory. This two-tier model is consistent with how EPA guidance recommends structuring cyanotoxin monitoring: rapid qualitative screening drives response decisions in the field, while quantitative lab methods provide the data needed for regulatory reporting and long-term trend analysis. Explore the full range of lateral flow assays, ELISA kits, and molecular detection tools available at the Attogene product list, or contact the team to discuss building a panel tailored to your specific waterbodies, matrices, and reporting requirements.

---

Guanitoxin’s rapid environmental degradation makes it incompatible with many standard analytical workflows used for more stable toxins. Its instability causes it to break down before conventional sample preparation and HPLC-based analysis can be completed, leading to systematic underdetection. Regulatory frameworks have not yet established required monitoring limits for the toxin, further reducing the incentive for monitoring programs to invest in specialized detection methods.

Guanitoxin is primarily produced by freshwater cyanobacteria including Sphaerospermopsis torques-reginae, certain Anabaena species, and Dolichospermum species. These genera overlap significantly with those known to produce anatoxin-a and saxitoxin, which is why neurotoxin co-occurrence monitoring is a practical near-term strategy for managing guanitoxin risk in the absence of widely available direct detection methods.

Attogene does not currently offer a guanitoxin-specific immunoassay, reflecting the broader state of the field. However, Attogene’s anatoxin-a detection kits use a receptor-based mechanism that engages the same acetylcholinesterase inhibition pathway as guanitoxin, making them a meaningful component of a neurotoxin surveillance strategy while the field continues to develop guanitoxin-specific tools. Contact Attogene to discuss multi-toxin panel design for your monitoring program.

Lateral flow assays (LFAs) are rapid, field-deployable qualitative or semi-quantitative tests that return a result in 15 to 30 minutes with minimal equipment — ideal for on-site triage and bloom response decisions. ELISA kits provide quantitative concentration data in a controlled laboratory setting with higher sensitivity and the precision required for regulatory reporting, including EPA Method 546 compliance. Best-practice HAB monitoring programs use both: LFAs in the field to drive rapid management decisions, and ELISA in the lab for confirmation and trend data.